Showing results (291-300 of 306) with videos related to
Sort By:
Pageof 31
Cardiovascular Drug Reviews|August 3, 2001
Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531J M Dogné, S Rolin, X de Leval, et al.International Journal of Pharmaceutics|July 25, 2007
In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxelF Lacoeuille, F Hindre, F Moal, et al.Archives of Physiology and Biochemistry|February 20, 2004
Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitorB Lambermont, P Kolh, J-M Dogné, et al.The Journal of Clinical Endocrinology and Metabolism|February 26, 2000
Response of leucine metabolism to hyperinsulinemia in hypothyroid patients before and after thyroxine replacementC Rochon, I Tauveron, C Dejax, et al.Cancer|July 27, 1999
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot studyP Menei, M C Venier, E Gamelin, et al.The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 21, 2007
Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapyE Jestin, M Mougin-Degraef, A Faivre-Chauvet, et al.Human Gene Therapy|January 20, 1997
Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cellsG Liu, K J Excoffon, P Benoit, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|December 9, 2010
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1M Weyland, F Manero, A Paillard, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|June 1, 2014
Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoringA-L Lainé, J Gravier, M Henry, et al.Journal of Molecular Medicine (Berlin, Germany)|October 30, 1999
Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin: cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol effluxU Daum, C Langer, N Duverger, et al.Pageof 31